Navigation Links
New Study Examines the Evolving Role of Medical Science Liaisons in the Medical Device Sector
Date:3/2/2012

CHAPEL HILL, N.C., March 2, 2012 /PRNewswire/ -- Medical Science Liaisons (MSLs) have become a key link between the medical device industry and critical stakeholders such as thought leaders that drive marketplace success. And the role of MSLs - also called medical specialists - will grow even more in the coming years as the device industry turns to them to build relationships across a diverse set of customers.

Given the expanding role of MSLs, it's critical for organizations to continually improve their MSLs group's activities and services to ensure they are creating value for diverse customer groups. To meet this need, Best Practices, LLC conducted a comprehensive research study of the structure, management and services that are hallmarks of successful MSL groups within device organizations.

"Medical Science Liaison Services Excellence: Generating Value for Diverse Customer Groups within the Medical Device Industry" provides benchmarks and insights across the many services and stakeholders that MSLs are involved with as part of their growing responsibilities at device organizations.

For instance, 75 percent of research participants believe that internal managed care groups will be users of MSL support services in the next two years. Thus, MSLs will need to understand how payer groups work and how best to serve internal constituents working with them. Currently, only about 25 percent of device companies regularly support internal payer groups, according to the research.

Study topics include:

  • Key Opinion Leaders Management
  • MSL Internal Services and Activities
  • MSL Services and Payer Education and Support
  • MSL Services and Hospital/Health Care Access
  • Emerging Trends and Mitigating Risks
  • MSL Services and Physician Education
  • MSL Services and Patient Education and Advocacy Support
  • MSL Group Structure and Oversight
  • MSL Activities Throughout Lifecycle

This 77-page study is based on research and information provided by eight medical device executives from eight companies.

Specifically, this primary research delivers valuable insights into the structure and overall organization of Medical Science Liaisons Services, including geographic span, oversight responsibility and services provided to various customer segments. The study offers powerful insights that device companies can use to effectively organize and deploy MSLs.

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1150.htm. For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):